NYSEAMERICAN:MTNB - Matinas BioPharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.38
  • Forecasted Upside: 389.13 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.69
▼ -0.02 (-2.82%)

This chart shows the closing price for MTNB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Matinas BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MTNB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MTNB

Analyst Price Target is $3.38
▲ +389.13% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Matinas BioPharma in the last 3 months. The average price target is $3.38, with a high forecast of $4.00 and a low forecast of $3.00. The average price target represents a 389.13% upside from the last price of $0.69.

This chart shows the closing price for MTNB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Matinas BioPharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/3/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/11/2021Piper SandlerDowngradeOverweight ➝ Neutral
3/30/2021HC WainwrightReiterated RatingBuy$4.00 ➝ $3.00
2/15/2021AegisReiterated RatingBuy
1/29/2021Maxim GroupReiterated RatingBuy$3.00
1/4/2021Piper SandlerBoost Price TargetOverweight$1.80 ➝ $4.00
11/6/2020Maxim GroupInitiated CoverageBuy$3.00
8/13/2020AegisBoost Price TargetBuy$3.25 ➝ $3.50
8/11/2020HC WainwrightReiterated RatingBuy$4.00
6/2/2020AegisReiterated RatingBuy
5/23/2020Maxim GroupInitiated CoverageBuy$3.00
5/13/2020Maxim GroupReiterated RatingBuy
4/1/2020Maxim GroupInitiated CoverageBuy$3.00
3/6/2020Maxim GroupReiterated RatingBuy
1/26/2020Piper SandlerInitiated CoverageOverweight$3.00
1/23/2020SunTrust BanksInitiated CoverageBuy$3.00
1/9/2020AegisInitiated CoverageBuy$3.50
12/20/2019HC WainwrightReiterated RatingBuy$4.00
9/26/2019Maxim GroupReiterated RatingBuy$3.00
8/14/2019HC WainwrightReiterated RatingBuy$4.00
6/26/2019HC WainwrightReiterated RatingBuy
6/26/2019HC WainwrightInitiated CoverageBuy ➝ Buy$4.00
5/17/2019BTIG ResearchInitiated CoverageBuy$5.00
5/16/2019Maxim GroupReiterated RatingBuy$5.00
2/11/2019Roth CapitalReiterated RatingBuy
2/11/2019Roth CapitalInitiated CoverageBuy$4.75
11/12/2018Maxim GroupBoost Price TargetBuy ➝ Buy$2.00 ➝ $5.00
8/13/2018Maxim GroupLower Price TargetBuy ➝ Buy$3.00 ➝ $2.00
7/10/2018Maxim GroupLower Price TargetBuy ➝ Buy$4.00 ➝ $3.00
5/10/2018Maxim GroupSet Price TargetBuy$4.00
4/23/2018Maxim GroupSet Price TargetBuy$4.00
3/19/2018Maxim GroupSet Price TargetBuy$6.00
8/10/2017Roth CapitalSet Price TargetBuy$9.00
8/8/2017Maxim GroupSet Price TargetBuy$6.00
7/10/2017Roth CapitalReiterated RatingBuy
7/10/2017Roth CapitalInitiated CoverageBuy$9.00
6/26/2017Maxim GroupReiterated RatingBuy$6.00
6/5/2017Maxim GroupSet Price TargetBuy$6.00
5/16/2017Maxim GroupSet Price TargetBuy$6.00
4/3/2017Maxim GroupReiterated RatingBuy$6.00
3/28/2017AegisReiterated RatingBuy ➝ Positive$8.00
3/27/2017Maxim GroupReiterated RatingBuy$6.00
3/2/2017Maxim GroupSet Price TargetBuy$6.00
11/21/2016Maxim GroupInitiated CoverageBuy
11/1/2016AegisInitiated CoverageBuy
(Data available from 7/28/2016 forward)
Matinas BioPharma logo
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Read More

Today's Range

Now: $0.69
Low: $0.67
High: $0.71

50 Day Range

MA: $1.11
Low: $0.88
High: $1.74

52 Week Range

Now: $0.69
Low: $0.66
High: $2.22

Volume

1,020,257 shs

Average Volume

2,902,419 shs

Market Capitalization

$140.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Matinas BioPharma?

The following Wall Street analysts have issued stock ratings on Matinas BioPharma in the last year: Aegis, HC Wainwright, Maxim Group, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for MTNB.

What is the current price target for Matinas BioPharma?

4 Wall Street analysts have set twelve-month price targets for Matinas BioPharma in the last year. Their average twelve-month price target is $3.38, suggesting a possible upside of 389.1%. Piper Sandler has the highest price target set, predicting MTNB will reach $4.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $3.00 for Matinas BioPharma in the next year.
View the latest price targets for MTNB.

What is the current consensus analyst rating for Matinas BioPharma?

Matinas BioPharma currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MTNB will outperform the market and that investors should add to their positions of Matinas BioPharma.
View the latest ratings for MTNB.

What other companies compete with Matinas BioPharma?

How do I contact Matinas BioPharma's investor relations team?

Matinas BioPharma's physical mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company's listed phone number is +1-908-4431860 and its investor relations email address is [email protected] The official website for Matinas BioPharma is www.matinasbiopharma.com.